Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

January 15, 2018

FDA Approves Lynparza to Treat BRCA-mutated Metastatic Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib) for a difficult-to-treat form of metastatic breast cancer. Patients with BRCA-mutated, HER2-negative breast cancer who have previously been treated ... Read more

December 18, 2017

Talazoparib Prevented Disease Progression in Breast Cancer with BRCA Mutations in Phase 3 Trial

News

Pfizer’s talazoparib prolonged the time until disease progression or death in breast cancer patients with inherited BRCA mutations, compared to standard chemotherapy, in a Phase 3 trial of the treatment. ... Read more

December 8, 2017December 8, 2017

Artificial Intelligence Tested to Improve Mammogram Screening

News

Researchers in the United Kingdom are launching a project to study if artificial intelligence (AI) could improve the detection of breast cancer in mammograms. If successful, AI-based screening is expected ... Read more

December 6, 2017

Early Cancer Metastasis Discovery May Allow for Better Treatment Decisions

News

When tumor cells become too densely packed, they start developing blood vessel-like structures — an early step in the process of cancer metastasis, researchers at the University of California, San Diego ... Read more

November 22, 2017November 22, 2017

Overweight Women May Need More Mammograms, Study Contends

News

Overweight women might need mammograms more often because being overweight increases the risk that a tumor will become large before it is detected, researchers from Karolinska Institutet in Sweden argue ... Read more

November 17, 2017November 17, 2017

FDA Approves Faslodex in Combo with Verzenio for Women with Advanced Breast Cancer

News

The U.S. Food and Drug Administration (FDA) expanded to use of AstraZeneca’s Faslodex (fulvestrant) to include it in combination with Verzenio (abemaciclib) to treat HR-positive, HER2-negative advanced or metastatic breast ... Read more

November 13, 2017November 13, 2017

Novartis to Request Kisqali’s Approval to Treat Premenopausal Women on Basis of Phase 3 Trial

News

Novartis plans to begin work with regulatory authorities to request that Kisqali (ribociclib) be approved as a first-line treatment for premenopausal women with HR-positive, HER2-negative advanced breast cancer. This decision ... Read more

November 8, 2017

BriaVax Breast Cancer Vaccine Development Going According to Plan, Company Says

News

BriaCell Therapeutics’ Phase 1/2a study of the breast cancer vaccine BriaVax is proceeding according to plan, the company recently announced. Six patients with advanced breast cancer have received the therapeutic ... Read more

October 23, 2017

Standard-of-Care Control Groups in Breast Cancer Trials Often Not Standard, Study Says

News

Many breast cancer clinical trials that are described as comparing a new treatment with a standard-of-care therapy do not actually make such a comparison, University of Sydney researchers argue. That’s because ... Read more

October 2, 2017

FDA Approves Eli Lilly’s Verzenio for Certain Types of Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company’s Verzenio (abemaciclib) for the treatment of HR-positive, HER2-negative type of advanced or metastatic breast cancer if a ... Read more